Focusing on infection prevention to slow antimicrobial resistance rates

Doshi’s article on antimicrobial drug development shows that the Food and Drug Administration is just as vulnerable to a knee jerk reaction as everyone else.1 While sharing Doshi’s concerns, I am struck that the article’s title shows that however many new antimicrobial agents are approved, validly or not, their shelf life will be limited.

Firstly, all the agents mentioned are variations on a theme, so any established resistance …